AC Immune (ACIU) Scheduled to Post Quarterly Earnings on Friday

AC Immune (NASDAQ:ACIU) is set to issue its quarterly earnings data on Friday, April 26th.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, March 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $16.71 million for the quarter, compared to analysts’ expectations of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Trading Down 0.4 %

Shares of ACIU opened at $2.37 on Thursday. The business’s fifty day simple moving average is $3.12 and its two-hundred day simple moving average is $3.34. AC Immune has a 12 month low of $1.78 and a 12 month high of $5.14. The company has a market cap of $234.39 million, a price-to-earnings ratio of -3.34 and a beta of 1.00.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of AC Immune in a report on Friday, March 15th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.